
Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update
TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate …